Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Abstract Background Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular hetero...

Full description

Bibliographic Details
Main Authors: Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi, Matteo Fassan
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:http://link.springer.com/article/10.1186/s40425-019-0788-5

Internet

http://link.springer.com/article/10.1186/s40425-019-0788-5

Similar Items